Linkedin Twitter
Contact

News
Filter by Category

Awards
Data
Deals
Milestones
Patents

Filter by Year

2021
2020
2019
Earlier

  • News Article
Back to Overview

Synaffix Appoints Mr. Anthony DeBoer as Director of Business Development

The Netherlands, 01 October 2014 – Synaffix BV, today announced the appointment of Mr. Anthony DeBoer as its Director of Business Development.

Previously, Mr. DeBoer served as the Associate Director of Business Development at Allozyne Inc., a Seattle-based biotechnology and protein therapeutics company. While at Allozyne, he was focused on key partnering efforts around its ADC platform technology as well as preclinical to Phase III-ready pipeline programs, leading up to the acquisition by MedImmune.

Back to Overview
Contact

 

+31-88-022-4505

Kloosterstraat 9
5349 AB Oss
The Netherlands

Corporate
Careers
Downloads
Privacy Policy
Join Mailing List

Copyright Synaffix BV 2021. All Rights Reserved

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace® Polar Spacer

Forming an integral part of every toxSYN®

linker-payload, HydraSpace® bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace
HydraSpace®

GlycoConnect®  design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect®

GlycoConnect® ADCs
Metal-Free Click Conjugation
Enzymatic ADCs (Review)
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1

toxSYN® Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
toxSYN®
Linker-Payload		 Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent		 Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors		 Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based
* Patent protection filed by Synaffix, beyond the claims of GlycoConnect® and HydraSpace® ** N-6-aminohexanoyl-maytansine (Ahx-maytansine)